- Avricore, through its subsidiary HealthTab(TM), will now distribute Abbott’s ID Now(TM) molecular testing device following the first amendment to the supplier distribution agreement between the two companies
- This amendment will allow for an improvement in onsite testing and reporting capabilities for SARS-CoV-2, along with RSV, Influenza A & B and Strep
- Avricore also announced its partnership with Ellerca Health Inc., in a move to utilize Ellerca’s technologies and service while focusing on diabetes screening and management
- Avricore also marked a huge milestone with the HealthTab(TM) system’s deployment in specific Shoppers Drug Mart(R) locations
On July 26, 2021,
Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF) announced that it had signed its first amendment to its supplier distribution agreement with Abbott.
The initial agreement, which was signed on May 31, 2021, was meant to allow HealthTab(TM) Inc., a subsidiary owned by Avricore, to distribute Canada Abbott’s Afinion(TM) 2 plus associated tests for heart disease and diabetes screening in community pharmacies (
https://ibn.fm/qUT1L).
With the amendment, HealthTab(TM) can now distribute Abbott’s ID Now(TM) molecular testing device. This will further strengthen onsite testing and reporting capabilities for SARS-CoV-2, along with RSV, Influenza A & B and Strep. While announcing the amendment, Hector Bremner, the Chief Executive Officer (“CEO”) of Avricore, noted:
“With ID Now(TM) on the HealthTab(TM) network in community pharmacy, patients can know what they have and get focused treatment and prevent spread through better information.”
Avricore is a pharmacy service innovator whose focus is on acquiring and developing early-stage technologies that help move pharmacy forward. Through HealthTab(TM), its wholly-owned subsidiary, the enterprise looks to develop actionable health information more accessible to everybody by creating the world’s largest network of rapid testing devices within community pharmacies.
In line with this vision to make testing accessible to everyone, the company announced its partnership with Ellerca Health Inc. (
https://ibn.fm/nKlGd). This move was intended to utilize Ellerca’s technologies and service, focusing on diabetes screening and management. Ellerca has made a name for itself, given its commitment to improving patient care through innovation and leading technologies. Known for its 360Care(TM) application, the company allows patients to control their treatment, thereby reducing the time of reactionary treatment, along with the costs associated with that.
“We’ve already identified several projects where HealthTab(TM) and 360Care(TM) can work together to support patient needs in pharmacy, and we look forward to continuing to work towards collaborating on these efforts,” noted Mr. Bremner.
While announcing the collaboration, Daniel Yeboah, the General Manager (“GM”) of Ellerca Health, noted:
“Working together with Avricore Health will allow our members to have easy access to A1C testing at local pharmacies and improve the speed of results.”
He also added:
“By bringing critical health data to a patient’s mobile device quickly and providing the coaching needed to understand the risks, we can continue to move away from just treating disease and support better health outcomes for people living with chronic conditions like diabetes.”
To further create the world’s largest network of rapid testing devices within community pharmacies, Avricore, on August 10, 2021, announced that patient testing had begun on the HealthTab(TM) platform within select Shoppers Drug Mart(R) pharmacies (
https://ibn.fm/tpewV). These pharmacies will now be offering screening tests to patients with known pre-diabetes conditions and those who have already been diagnosed with diabetes.
“We are very excited to pilot Point of Care Testing with HealthTab and the Afinion 2 analyzer at select Shoppers Drug Mart(R) pharmacies,” noted Frank Hack, the Director of Complex Care at Shoppers Drug Mart. “We are committed to improving access to care through our pharmacy network and enabling our pharmacists to drive improved patient outcomes by providing value-added patient care services,” he added.
Initially, the program involved 11 locations. However, ever since, the agreement has been updated to 15 different locations. Beta-testing at the first store proved successful, with over 600 results reported and over 90 patients tested. Avricore reckons that this is a huge milestone for the company and an initiative that will continue to advance the company’s mission of making actionable health information more accessible for everybody by creating a network of rapid testing in pharmacy.
For more information, visit the company’s website at
www.AvricoreHealth.com.
NOTE TO INVESTORS: The latest news and updates relating to AVCRF are available in the company’s newsroom at
https://ibn.fm/AVCRF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.